Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Nurix Therapeutics, Inc. logoNurix Therapeutics, Inc.

NRIX · Nasdaq · USD · Market cap $1.6B · 317 employees

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory condit…

FAIL · Does not pass the screen
12.85 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price12.85 USD at the 20 Nov 2026 close
  • Fair valueUnder review: our model's value is 2.45x the price, above our 2.00x limit.
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 28.42)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-20).

Current read
Distribution ?
Screened · screened 2026-11-20
  • Trend Distribution
  • Insiders insiders sold, $74,562, latest filing 2026-11-04
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 28.42, read 2026-11-19
  • Ethical does not pass the values gate
Price12.85 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-09Read Distribution15.30-16.0% to today ✓Accumulation gives way to Distribution after a 41% slide in 2 weeks
2026-10-26Read Accumulation26.02-50.6% to today Markdown gives way to Accumulation
2026-10-02Read Markdown25.41-49.4% to today ✓Accumulation gives way to Markdown after a 5% slide in 3 weeks
2026-09-08Read Accumulation26.88-52.2% to today Markup gives way to Accumulation after a 16% rise in 5 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Nurix Therapeutics, Inc. holds its Distribution at $12.85. Consolidating, no directional conviction, held for 10 days.

As held on the ledger · 2026-11-20
PhaseDistribution · caution
Quantitative stateConsolidating, no directional conviction, held for 10 days
Price at the screen$12.85
Valuation5.86 trailing · -11.16 forward price to earnings
Values screenFAIL · score 70.0
Beta1.78
The Workings

Five Screens: NRIX's Results

FAIL. Interest-bearing securities

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 8.10% Below 33% Pass
Interest-bearing cash 50.28% Below 33% Fail
Receivables 35.89% Below 49% Pass
Revenue purity 26.16% Below 5% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Nurix Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 50% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when NRIX's ethical verdict changes

Today NRIX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 2.45x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

Method.

The Street's Range
20.00Street low 34.50Street average 41.00Street high 12.85Price

Street: 14 covering, consensus Strong Buy. Average target +168%.

Chart
The Business, in Plain Words

Clinical stage bets rarely survive revenue collapse

Developing a new cancer drug is like funding a marathon runner who has not even reached the starting line. Nurix focuses on small molecule therapies for oncology and inflammation, yet revenue has fallen 80% while losses remain total and return on equity sits at minus 80%. Analysts see upside to $34, but the business still burns cash with no approved products and an unknown moat.

The 45% gap to our fair value looks tempting on paper, yet opportunity rating stays at none. Negative forward earnings, zero profit margin and an early pipeline mean any valuation rests on future trial success that has not arrived. Ethical screen clears, but that alone does not create a durable business.

High failure rates in the clinic, repeated dilution risk and execution uncertainty keep us on the sidelines. The numbers show a company still far from cash flow, not a bargain in disguise. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-11.2x
Trailing P/E5.9xvery cheap relative to earnings
EPS, trailing2.43
EPS, forward-1.28
Revenue growth+8,426.3%growing very fast
Profit margin42.0%highly profitable on every dollar of sales
Return on equity44.0%an exceptional return on shareholder capital
FCF yield15.00%
Debt to equity0.07minimal debt: a conservative balance sheet
Current ratio8.44comfortably covers its short-term bills
Beta1.78much more volatile than the market
Short interest, float0.18%
52-week range12.43 - 28.23
Market cap$1.6B
Employees317

NRIX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Distribution $14.10 -8.9% Entry 14
2026-11-16 Distribution $15.48 +1.2% Entry 13
2026-11-09 Distribution · changed $15.30 -42.9% Entry 12

The framework has shifted from accumulation to distribution since the last review.

2026-11-02 Accumulation $26.80 +3.0% Entry 11
2026-10-26 Accumulation · changed $26.02 +9.9% Entry 10

The framework has shifted from markdown to accumulation since the last review. Since the last review it saw its composite score rise.

2026-10-19 Markdown $23.67 +5.9% Entry 9
2026-10-12 Markdown $22.35 -1.1% Entry 8
2026-10-11 Markdown $22.60 -11.1% Entry 7
2026-10-02 Markdown · changed $25.41 -5.5% Entry 6

The framework has shifted from accumulation to markdown since the last review. Earnings landed in this window.

2026-09-08 Accumulation · changed $26.88 +16.2% Entry 5

The framework has shifted from markup to accumulation since the last review. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on NRIX

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in NRIX's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · NRIX
DateInsiderTitleTypeSharesValue
2026-11-04 Van Houte Hans CFO S - Sale 4,769 $74,562
2026-11-02 Ring Christine GC S - Sale+OE 16,715 $431,904
2026-10-14 Gregory Julia P Dir S - Sale+OE 22,583 $528,528
2026-10-02 Ring Christine GC S - Sale+OE 5,786 $134,149

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $16.28 -6.3% · $937 -6.3%
2 months $16.03 -4.9% · $951 -4.9%
3 months $15.61 -2.3% · $977 -2.3%
6 months $19.07 -20.0% · $800 -20.0%
1 year $12.79 +19.2% · $1,192 +19.2%
2 years $15.32 -0.5% · $995 -0.5%
3 years $10.14 +50.4% · $1,504 +50.4%
5 years $28.95 -47.3% · $527 -47.3%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever NRIX does next, these words stay.

Nurix Therapeutics, Inc. · NRIX · Distribution · $12.85
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.